Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels

For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels HASBROUCK HEIGHTS, NJ (May 13, 2014) Nymox Phar maceutical Corp oration (NASDAQ: NYMX) reported today positive new study findings show ing that the Company’s NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treat ed men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). This data is consistent with the large body of existing data for men treated with NX-1207 (n over 1,000) showing a favorable sexual profile for the treatment. One of the major problems with current prostate treatment s for localized prostate cancer (radical prostatectomy, external beam radiation, or brachyt herapy) is the relatively high incidenc e of reported sexual dysfunction post- treatment. In now 8 completed studies, NX-1207 treatment has shown to have no significant adverse effect post- treatment on sexual function or testosterone levels. For the NX03-0040 study, previously reported study resu lts showed that patients with NX-1207 treatment had significantly less Gleason grade progression, lower aver age PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls. To date, NX-1207 has had an excellent safety profile as both a treatment for benign prostatic hyperplasia (BPH) and localized low-risk prostate cancer. In the current trial, a new high dose of drug (15 mg) was safely used without drug-related adverse effects. NX-1207 has shown safety in repeat injection studies (NX02-0020 and NX02-0022). The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/or limit usage to single treatments due to drug neutralizing effects. NX-1207 is in Phase 3 development in the US and Europe for benign prostatic hyperplasia (BPH) also referred to as prostate enlargement, a common affliction of middle-aged and elderly men, affecting up to half of men over the age of 50. The Company's European partner for BPH is Recordati S.p.A. More information about Nymox is available at www.nymox.com, email: [email protected], or 800-936-9669. This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such st atements will prove to be accu rate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. ### NEWS RELEASE

The release as fetched from its publisher. nymox.com ↗